8-oxo-2-(3-pyridyl)-9-[2-(trifluoromethyl)phenyl]-7-hydropurine-6-carboxamide | 1022156-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 8-oxo-2-(3-pyridyl)-9-[2-(trifluoromethyl)phenyl]-7-hydropurine-6-carboxamide
• 英文别名: 8-oxo-2-pyridin-3-yl-9-[2-(trifluoromethyl)phenyl]-7H-purine-6-carboxamide
• CAS: 1022156-33-7
• 化学式: C₁₈H₁₁F₃N₆O₂
• 分子量: 400.32
• InChiKey: NPVCMGDLYBFEOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS
  申请人：Signal Pharmaceuticals LLC

  公开号：EP2078018B1

  公开（公告）日：2012-03-14
• TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
  申请人：Signal Pharmaceuticals, LLC

  公开号：US20130102613A1

  公开（公告）日：2013-04-25

  Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
• IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS
  申请人：Ning Yuhong L.

  公开号：US20130158023A1

  公开（公告）日：2013-06-20

  Provided herein are methods for predicting the LKB1 status of a patient or a biological sample, comprising the measurement of particular gene expression levels relative to a set of reference levels that represent the gene expression level of a biological wild-type sample without LKB1 gene or protein loss or mutation and the gene expression level of a reference sample with LKB1 gene or protein loss or mutation. Further provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by particular gene expression levels.
• US9493466B2
  申请人：——

  公开号：US9493466B2

  公开（公告）日：2016-11-15